Filtered By:
Specialty: Neuroscience
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 28 results found since Jan 2013.

A Successful Quality Improvement Project for Detection and Management of Acute Stroke in Hospitalized Patients
CONCLUSION: The new IHS protocol has led to a marked increase in cases identified, rapid evaluation, and high utilization rate of acute stroke therapies.
Source: Journal of Neuroscience Nursing - July 30, 2020 Category: Neuroscience Tags: Clinical Nursing Focus Source Type: research

National data on stroke outcomes in Thailand
In conclusion, the prevalence and outcomes of stroke in Thailand were comparable with other countries. The era of thrombolytic therapy has just begun in Thailand.
Source: Journal of Clinical Neuroscience - January 14, 2015 Category: Neuroscience Source Type: research

Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
CONCLUSIONS: RSG treatment protects against BBB damage and ameliorates HT in delayed tPA-treated stroke mice by activating PPAR-γ and favoring microglial polarization toward anti-inflammatory phenotype. PMID: 31756041 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - November 21, 2019 Category: Neuroscience Authors: Li Y, Zhu ZY, Lu BW, Huang TT, Zhang YM, Zhou NY, Xuan W, Chen ZA, Wen DX, Yu WF, Li PY Tags: CNS Neurosci Ther Source Type: research

Therapeutic strategy against ischemic stroke with the concept of neurovascular unit
Publication date: Available online 1 April 2019Source: Neurochemistry InternationalAuthor(s): Tomohiko Ozaki, Hajime Nakamura, Haruhiko KishimaAbstractStroke is one of the leading causes of death and disability globally. Although thrombolytic therapy by t-PA and mechanical thrombectomy have improved outcomes of ischemic stroke patients, both of these approaches are applicable to limited numbers of patients owing to their time constraints. Therefore, development of other treatment approaches such as developing neuroprotective drugs and nerve regeneration therapy is required to overcome ischemic stroke. The concept of the ne...
Source: Neurochemistry International - April 2, 2019 Category: Neuroscience Source Type: research

Thrombolysis beyond 4.5  h in Acute Ischemic Stroke
AbstractPurpose of ReviewThe purpose of this article is to review the current approaches using neuroimaging techniques to expand eligibility for intravenous thrombolytic therapy in acute ischemic stroke patients with stroke of unknown symptom onset.Recent FindingsIn recent years, several randomized, placebo-controlled trials have shown neuroimaging-guided approaches to be feasible in determining eligibility for alteplase beyond 4.5  h from last known well, and efficacious for reducing disability. DWI-FLAIR mismatch on MRI is an effective tool to identify stroke lesions less than 4.5 h in onset in patients with stroke of ...
Source: Current Neurology and Neuroscience Reports - June 29, 2020 Category: Neuroscience Source Type: research

Direct admission to stroke centers reduces treatment delay and improves clinical outcome after intravenous thrombolysis
Publication date: Available online 9 January 2016 Source:Journal of Clinical Neuroscience Author(s): Dae-Hyun Kim, Hee-Joon Bae, Moon-Ku Han, Beom Joon Kim, Sang-Soon Park, Tai Hwan Park, Kyung Bok Lee, Kyusik Kang, Jong-Moo Park, Youngchai Ko, Soo Joo Lee, Jay Chol Choi, Joon-Tae Kim, Ki-Hyun Cho, Keun-Sik Hong, Yong-Jin Cho, Dong-Eog Kim, Jun Lee, Juneyoung Lee, Mi Sun Oh, Kyung-Ho Yu, Byung-Chul Lee, Hyun-Wook Nah, Jae-Kwan Cha We aimed to examine whether direct access to hospitals offering intravenous thrombolysis is associated with functional outcomes in patients with acute ischemic stroke tr...
Source: Journal of Clinical Neuroscience - January 11, 2016 Category: Neuroscience Source Type: research

Evaluation of functional outcome measured by modified Rankin scale in rtPA treated patients with acute ischemic stroke.
Authors: Georgievski-Brkic B, Savic M, Nikolic D, Nikcevic L, Vukicevic M, Kozic D Abstract Aim of our study was to assess functional outcome measured by modified Rankin scale (mRS) in patients that were treated with thrombolytic therapy-recombinant tissue plasminogen activator (rtPA) after acute ischemic stroke. The study included 100 participants that were treated after acute ischemic stroke. Analyzed parameters included: gender; age groups: age 54 and below (Groupup to-54), 55-64 (Group55-64), 65-74 (Group65-74), and 75 and above (Group75-up); cerebral blood flow (CBF) and cerebral blood volume (CBV). Considerin...
Source: Archives Italiennes de Biologie - March 23, 2017 Category: Neuroscience Tags: Arch Ital Biol Source Type: research

LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH
ConclusionDespite the proven causative relationship between severe HT and neurological deterioration in human stroke, rt-PA-triggered HT in mouse MCAo does not contribute to neurological deficit or simulate sICH. Model limitations, such as the long duration of occlusion required, the type of HT achieved and the timing of deficit assessment may account for this mismatch. Our results further suggest that blockade of LDL receptors improves stroke outcome irrespective of rt-PA, blood –brain barrier breakdown and HT.
Source: Fluids and Barriers of the CNS - November 21, 2017 Category: Neuroscience Source Type: research

A male Fabry disease patient treated with intravenous thrombolysis for acute ischemic stroke
We report a 38-year-old man with acute aphasia and a left M2 segment of the middle cerebral artery thrombus with no recanalization who was finally diagnosed with Fabry disease after left ventricular hypertrophy of undetermined cause had been identified. A gene test revealed a R227X mutation typical of Fabry disease with the classical phenotype. To our knowledge our patient is the first reported male Fabry patient who was given intravenous thrombolytic therapy and the first reported Fabry patient who received intravenous thrombolytic therapy between 3 and 4.5hours of the symptom onset. Despite favorable prognostic indicator...
Source: Journal of Clinical Neuroscience - January 14, 2015 Category: Neuroscience Source Type: research

In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors
Publication date: March 2015 Source:Journal of Clinical Neuroscience, Volume 22, Issue 3 Author(s): Santosh B. Murthy , Yogesh Moradiya , Shreyansh Shah , Aditi Shastri , Eric M. Bershad , Jose I. Suarez Data on thrombolysis outcomes in patients with primary brain tumors are limited. Our aim was to study stroke outcomes following thrombolysis in these patients in a population-based study. Patients with acute ischemic stroke who received thrombolysis were identified from the 2002–2011 USA Nationwide Inpatient Sample. We compared demographics, comorbidities, and outcomes between primary brain tumor-associated strokes (BT...
Source: Journal of Clinical Neuroscience - February 16, 2015 Category: Neuroscience Source Type: research

Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy
Conclusions: Taken together, these results indicate an injurious nNOS/peroxynitrite/AMPK cycle following stroke, and GSNO treatment of IR inhibits this vicious cycle, resulting in neuroprotection and improved neurological function. GSNO is a natural component of the human body, and its exogenous administration to humans is not associated with any known side effects. Currently, the FDA-approved thrombolytic therapy suffers from a lack of neuronal protective activity. Because GSNO provides neuroprotection by ameliorating stroke’s initial and causative injuries, it is a candidate of translational value for stroke therapy.
Source: BMC Neuroscience - July 15, 2015 Category: Neuroscience Authors: Mushfiquddin KhanTajinder DhammuFumiyo MatsudaAvtar SinghInderjit Singh Source Type: research

Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke
Abstract Oxidative stress is one of the main mechanisms implicated in the pathophysiology of inflammatory and neurodegenerative diseases of the central nervous system (CNS). Uric acid (UA) is the end product of purine catabolism in humans, and it is the main endogenous antioxidant in blood. Low circulating UA levels have been associated with an increased prevalence and worse clinical course of several neurodegenerative and inflammatory diseases of the CNS, including Parkinson’s disease and multiple sclerosis. Moreover, the exogenous administration of UA exerts robust neuroprotective properties in experimental m...
Source: Current Neurology and Neuroscience Reports - December 28, 2015 Category: Neuroscience Source Type: research

Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine
Conclusions: Adequate initial dosing of antihypertensive treatment has the potential to reduce time to blood pressure control and possibly time to alteplase therapy. The optimal antihypertensive regimen for controlling blood pressure before alteplase therapy remains unclear.
Source: Journal of Neuroscience Nursing - November 5, 2015 Category: Neuroscience Tags: Pharmacology Update Source Type: research

Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study
Treatment options for anticoagulated patients presenting with ischemic stroke are limited. Off-label use of idarucizumab to rapidly reverse the anticoagulant effect of dabigatran may ensure eligibility for thrombolytic therapy with alteplase. This case describes a 77-year-old white male who presented to the hospital 89 minutes after sudden onset of right-sided hemiparesis, dysarthria, and facial palsy. Significant history included atrial fibrillation and previous right-sided cortical stroke. Medication reconciliation revealed he was taking dabigatran 150 mg twice a day, with the last dose being 179 minutes before presentat...
Source: Journal of Neuroscience Nursing - January 8, 2019 Category: Neuroscience Tags: Case Study Source Type: research

Evaluation of the role of susceptibility-weighted imaging in thrombolytic therapy for acute ischemic stroke
Publication date: Available online 20 February 2017 Source:Journal of Clinical Neuroscience Author(s): Guangjian Zhao, Ling Sun, Ziran Wang, Liquan Wang, Zhongrong Cheng, Hongyan Lei, Daiqun Yang, Yansen Cui, Shirui Zhang We inspected low-intensity venous signals and microbleeds in patients with acute ischemic stroke (AIS) using susceptibility-weighted imaging (SWI) before and after administration of within-thrombolytic-time-window thrombolytic therapies, and observed their prognosis and safety, in order to guide individualized thrombolytic therapies. Patients with AIS were divided into groups A or B according to the pres...
Source: Journal of Clinical Neuroscience - February 20, 2017 Category: Neuroscience Source Type: research